Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin; Prasugrel
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- Acronyms HEIGHTEN
- 31 Aug 2018 Biomarkers information updated
- 20 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 20 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.